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TRIALS WITH COVARIATE ADAPTIVE RANDOMIZATION

Garrett Miller, MS
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Covariate adaptive randomization is an allocation procedure used in clinical trials that
seeks to balance treatment groups. While this method has been shown to reduce bias due to
imbalanced treatment groups, the effects of covariate adaptive randomization have not been
studied under seamless Phase II/Phase III clinical trials that incorporate short-term endpoint
information and treatment selection. Therefore, this analysis sought to determine whether
these adaptive randomization methods can be applied to seamless Phase II/Phase III trials
while preserving Type I error. In addition, this analysis sought to create R-packages that
employ seamless Phase II/Phase III techniques to provide analysis tools for future research.
Two covariate adaptive randomization schemes, Pocock and Simon’s procedure and
stratified permuted block randomization were applied to simulated datasets to determine
treatment groups. Seamless Phase II/Phase III clinical trials with two interim analyses were
then simulated with 10,000 repetitions to determine overall Type I error rates. Only the most
promising treatment group was selected to continue to the second interim analysis. Both
randomization procedures were compared against trials that used simple randomization to

allocate treatment groups. Ultimately, Type I error rates under the two adaptive techniques
were not preserved. Pocock and Simon’s randomization saw an inflated level of Type I error,
while stratified permuted block randomization resulted in lower levels of Type I error
compared to simple randomization. In addition, power calculations revealed that both
allocation methods resulted in lower levels of power compared to simple randomization.
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BACKGROUND
Clinical trials are an essential function of the healthcare system as they are the basis for
developing new therapies and treatments. Once a therapy has been developed, it must undergo a
multi-stage process to determine whether the therapy is safe, effective, and ready for public use.
Phase I of a clinical trial is used to administer the drug to a small set of patients in order to
determine that the drug is safe, and Phase II is used to determine an effective dosage and
treatment schedule from a variety of different treatment policies (Whitehead, 1991). Phase III
compares the chosen treatment policy to a control using a large number of patients, and Phase IV
is used to evaluate the performance of the drug after it has reached public market (Whitehead,
1991). To reduce the large costs and sample sizes associated with clinical trials, many methods
have been proposed that combine Phase II and Phase III into a single seamless trial that selects a
most promising treatment and compares that treatment to a control (Stallard & Todd, 2005).
While these methods have been shown to reduce overall sample size, further analysis needs to be
done to test these designs under different allocation schemes such as covariate adaptive
randomization. Since balancing covariates is an essential way to balance treatment groups with
respect to their key covariates, it is important to ensure that seamless Phase II/Phase III methods
are still valid under these allocation schemes (Ma, Hu, & Zhang, 2015). As there is always a
need to reduce overall costs associated with clinical trials, more analysis needs to be done to
develop the most ethical and efficient statistical methods used in clinical trials analysis.

Literature Review
In clinical trials, the Phase II trial, often described as an exploratory phase, is designed to
determine the most promising treatment out of several treatments or to determine the most
1

promising dosage of a treatment (Whitehead, 1991). Once a most promising treatment has been
determined, the trial proceeds to Phase III, where more long-term, primary effects are examined
to determine if the treatment is effective. Since patients are often recruited as the trail goes on, it
is possible to conduct analysis at interim points during the clinical trial, rather than waiting until
all the patients have been recruited. Such designs that use interim inspections are known as
sequential designs. These designs can lead to more ethical and efficient studies that stop analysis
before all patients are recruited.
Seamless Phase II/Phase III clinical trials seek to eliminate some of the information lost
between trials, as well as time lost to a recruitment by combining the phases into a seamless trial
design. These methods use both phases in a single trial that selects the most promising treatment,
while comparing the most promising treatment with a control to test for efficacy (Stallard &
Todd, 2005). There are many methods that have been proposed to conduct this combined design.
The seamless designs typically assume that there is a secondary endpoint available at the Phase
II portion for the trial, and a primary endpoint available during the Phase III portion of the trial.
Chow, Lu, and Tse (2007) developed a method that assumes there is a well-defined relationship
between the two endpoints, which allows for estimation of the primary endpoint using a linear
relationship. While this method was shown to reduce overall sample size, it does not incorporate
the sequential design that is often used in the confirmatory phase of a clinical trial as there are no
interim analyses. In addition, it is highly dependent on there being a well-defined relationship
between two normally distributed endpoints. Furthermore, it does include treatment selection
after the Phase II portion of the trial, which is a common element of Phase II/Phase III trials. To
allow for sequential design in combination with a Phase II/Phase III clinical trial, Stallard (2010)
considered a method that incorporates short-term endpoint information to select one treatment
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after the exploratory phase and incorporates the short-term endpoint information to develop the
stopping boundaries of the Phase III portion of the trial. This method was shown as a promising
way to incorporate short-term information while preserving Type I error rates; however, this
method was restricted to normally distributed endpoints, with a relatively high correlation
between the two endpoints. To address the possibility of differently distributed endpoints at the
separate analysis stages, Stallard and Todd (2003) proposed a seamless Phase II/Phase III design
that incorporates short-term endpoint information while considering a change in endpoint in
addition to treatment selection. This method considers a normally distributed short-term
endpoint, used to select one treatment to continue to the Phase III portion of the trial, and a
binomially distributed long-term endpoint, used to compare the most promising treatment to a
control in a sequential design. This design was able to reduce sample size while preserving Type
I error compared to a Phase II trial followed by a multi-stage Phase III trial.
Clinical trials allocate patients to treatment groups using randomization, to reduce
possible biases in the treatment arms. With simple randomization, there may be a bias associated
with clusters of patients receiving the same treatment. One method to reduce this bias is
covariate adaptive randomization. Covariate adaptive randomization assigns patients to treatment
groups while balancing possible covariates and preserving randomization. Typical methods in
covariate adaptive randomization change the allocation probabilities at each step, while adjusting
for previous assignments and the covariates of the subjects in order to reduce the possibility of
bias. (Kahan, Morris, 2001). While there are many techniques for performing this randomization,
only Pocock-Simons and stratified permuted block Design (SPB) were explored in this analysis.
Pocock and Simon (1975) use a generalized version of a minimization procedure that utilizes a
weighted sum to determine the differences between the number of patients over the separate

3

treatment groups. In stratified permuted block randomization, patients are assigned to strata that
are defined by characteristics and randomization is performed on each stratum in equal-sized
blocks. This is done to ensure that those baseline characteristic variables are balanced in each
block. (Kahan, Morris, 2001). These methods intend to minimize imbalance between treatment
groups, while reducing selection and accidental bias. Further analysis needs to be done to
determine how these covariate adaptive randomization techniques affect the results of a seamless
Phase II/Phase III trial design.
In any trial design, investigators seek to test a set of hypotheses: the null and alternate
hypothesis. The null assumes that a new treatment has no effect on an outcome of interest, while
the alternative assumes that there is an association. The null hypothesis enables investigators to
conduct statistical tests that assume a reasonable measure of doubt set by the Type I and Type II
error rates. Type I error, also known as false positive rate, occurs when the null hypothesis is
rejected when then the hypothesis is actually true in the population. The Type II error rate occurs
when the trial does not reject a null hypothesis that is actually false in the population. Ultimately,
a test can result in the 4 situations shown in Table 1.
Table 1: Type I and Type II Error
Truth

Association

No Association

Reject Null Hypothesis

Correct Decision

Type I Error

Fail to reject Null Hypothesis

Type II error

Correct

PUBLIC HEALTH SIGNIFICANCE
Clinical trials are an essential pathway for developing new and effective therapies. In
these trials, it is important to reduce possible harm caused to patients by giving them an
ineffective treatment. Using a sequential design allows investigators to stop recruitment if at any
4

point during the interim analyses, the treatment is determined to be effective, or futile. Costs of
clinical trials collected from seven major biopharma companies from 2010 to 2015 found that the
median cost of Phase I, Phase II, and Phase III trials was $3.4 million, $8.6 million, and $21.4
million respectively (Martin, Hutches, Hawkins, & Radnov, 2017). Methods such Stallard and
Todd (2005), Stallard (2010) and Chow, Lu and Tse (2007) use study designs that attempt to
reduce overall sample size, while still achieving a desired level of power. Therefore, these
methods can be employed to attempt to reduce some of the overall costs of clinical trials. In
addition, if it is determined that covariate adaptive randomization preserves Type I error rates in
these trials, further cost reduction could be achieved by reducing biases that would prevent
effective treatments from being discovered. With the vast number of clinical trials per year, it is
important to develop statistical methods that efficiently and ethically identify new treatments.

SPECIFIC AIMS
While previous studies were able to reduce overall sample size and preserve Type I error
rates in seamless Phase II/Phase III clinical trials, these methods have not been explored over
different sets of data. In addition, these methods have not been adapted to include different
allocation schemes such as covariate adaptive randomization. Based on these limitations, this
paper had two specific aims:
Aim 1: Develop R-packages for the three seamless Phase II/Phase III clinical trial designs
described by Stallard and Todd (2005), Stallard (2010), and Chow, Lu and Tse (2007) to
disseminate these innovative approaches to clinical trial practitioners.
Aim 2: Study whether Type I error rates in confirmatory seamless Phase II/Phase III clinical trial
incorporating short-term endpoint information are controlled under covariate adaptive
randomization.
5

In order to examine the results of the three seamless Phase II/Phase III clinical trial
designs, R-packages were created that followed the methodology described by each of the three
papers Stallard and Todd (2005), Stallard (2010), and Chow, Lu and Tse (2007).
In order to determine whether Type I error rates in a seamless Phase II/Phase III design
are controllable under covariate adaptive randomization, multiple factors were analyzed in order
to determine their influence on the Type I error. These factors included: randomization scheme,
correlation between study endpoints, and incorporation of Bernoulli covariates.

METHODS

Study Design
The designs described in Stallard and Todd (2005), Stallard (2010), and Chow, Lu, and
Tse (2007) were recreated in R-packages to allow for application of these methods for innovative
analysis. These packages were developed by following the methodology of each of the three
designs, while allowing for flexible options for trial practitioners.
The design in Stallard (2010) was adapted to incorporate covariate adaptive
randomization using both the Pocock-Simons and stratified permuted block design for treatment
allocation. Multiple parameter settings were evaluated with 10,000 simulated seamless Phase
II/Phase III trials under the Stallard (2010) design. Estimates for the overall Type I error rate
were taken from the 10,000 simulations to determine whether Type I error was conserved under
covariate adaptive randomization.

6

Data Collection
In the creation of the R-packages, no data was collected. All data was simulated in R to
ensure that the results align with those described in Stallard and Todd (2005), Stallard (2010),
and Chow, Lu, and Tse (2007). No data was collected from the three packages.

Study Sample
To adapt the design in Stallard (2010) study populations were simulated in R and
generated with the following steps: (1) generate Bernoulli covariates for each observation, (2)
assign observations to a treatment group based on covariate adaptive randomization design (3)
generate treatment responses.
For the design in Stallard (2010), the primary and secondary endpoints came from a
bivariate normal distribution. In each clinical trial simulation, two Bernoulli covariates were
created. The covariates are independent and follow the distribution in Equation (1).

𝑟 =

1 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑝
0 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 1 − 𝑝

(1)

After generating the Bernoulli covariates for each observation, the two covariate adaptive
randomization techniques, Pocock-Simons and stratified permuted block design, were used to
allocate observations to treatment groups. In Pocock-Simons design, were assigned to treatment
group A with the probability given in Equation (3).
𝑝 𝑚𝑖𝑛{𝐺 } = 𝐺
1
𝐺 =… = 𝐺
𝑃𝑟 (𝐴) =
𝑘
,( , )
⎨1 − 𝑝
⎪
}
⎩𝑘 − 1 𝑚𝑖𝑛{𝐺 ≠ 𝐺
⎧
⎪
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(2)

In Equation (2), 𝑘 is the number of treatment groups, and 𝑝 = 3/4 as suggested by the
original authors (Pocock & Simons, 1975). In Equation (2) 𝐺 is defined as the “total amount of
imbalance” which is taken as a weighted sum of the range of a set of non-negative integers
{𝑧 }

. Therefore, the treatment assignment that results in the smallest “total amount of

imbalance” was assigned with probability 𝑝.
For trials simulated using the stratified permuted block design, this analysis used four
levels of discretization with a block size of twenty. Details for the stratified permuted block
design can be found in (Broglio, 2018).
The primary and secondary responses were assigned based on the distribution shown in
Equation (3).
𝑋
~𝑁
𝑌

𝑎+𝑏 𝑧 +𝜏 𝑟 +𝜏 𝑟
𝜎
,
𝐴+𝐵 𝑧 +𝜏 𝑟 +𝜏 𝑟
𝜌𝜎 𝜎

In Equation (3), 𝑟 and 𝑟 are the Bernoulli covariates for the 𝑖

𝜌𝜎 𝜎
𝜎

(3)

patient defined in Equation (1).

In addition, 𝑏 and 𝐵 are the treatment effects for the short-term and long-term endpoints,
respectively. 𝜌 is the partial correlation between 𝑌 and 𝑋 , 𝜎 is the variance of the error term for
𝑋 , 𝜎 is the variance of the error term 𝑌 |𝑋. The remaining parameter values in this distribution
are shown in Table 3. 𝜏 and 𝜏 were included to account for the covariate values in the
distribution. 𝐴 and 𝑎 are the intercept terms. These terms were later excluded from this analysis.
Error was applied to each observation and came from the distribution in Equation (4).
𝜀~𝑁(0,1)

(4)

The primary and secondary responses, with their error terms, were generated for each of the
10,000 simulated clinical trials to give our study sample.
8

Data Analysis
To create R-packages for each of the three seamless Phase II/Phase III clinical trial
designs, the methodology for each paper was recreated in R.

R-package for A New Clinical Trial Design Combining Phases 2 and 3: Sequential Designs
with Treatment Selection and a Change of Endpoint.
To create an R-package that follows the design in Stallard and Todd (2005), R code was
written that followed the steps of the seamless Phase II/Phase III trial design defined in Stallard
and Todd (2005). The design takes any K number of treatments and observes two endpoints on
each patient. In order to make inferences about the different treatments, this method uses two test
statistics, corresponding to the Efficient Score and Fisher’s information for a given treatment.
The steps for this methodology are described in steps 1-6, with additional details available in
(Stallard & Todd, 2005).

(1) The two test statistics, efficient score and Fisher’s information, are given in detail by
Whitehead (1997). The statistics depend on the distribution of the outcome of interest. In the
case of the first interim analysis, the outcome is normally distributed. The treatment effect at
each analysis is shown in Equation (5).
( )

𝜃

( )

In Equation (5), V ,

( )

=

𝑍,

( )

𝑉,

(5)

corresponds to the Fisher’s information for secondary endpoint at the
( )

first interim analysis and Z , is the Efficient Score for the secondary endpoint at the first
interim analysis
9

(2) Out of the possible treatments, the most promising treatment is determined by using the
largest value for the treatment effect. Once the most promising treatment has been chosen,
the Efficient Score for this treatment is compared against a lower boundary. If does not cross
the lower boundary, then the trial proceeds to the next interim analysis. The rationale for
choosing a lower stopping boundary at this analysis can be found in Stallard and Todd (2005)
(3) At the next analysis, the outcome, which now comes from a binomial distribution, is used to
calculate the same test statistics as in the first analysis. In this case however, the formulae for
the test statistics depend on the binomial distribution (Whitehead, 1997). The treatment effect
is calculated in the same way as at the first interim analysis. Stopping boundaries are
calculated at the second interim analysis are based on the Fisher’s information at this point,
and the Fisher’s information obtained at the first interim analysis. The distribution of the
Efficient Score at this point is shown in Equation (6)
( )
( ) ( )
𝑍 , ~𝑁(𝜃 𝑉

−𝜌

𝑉

( )

𝑉

( )

𝜃

( )

𝑤ℎ𝑒𝑟𝑒 𝜌 = 𝜌

𝜌=

𝑐𝑜𝑣 𝑍

𝑉

( )

− 𝑧, 𝑉

𝑉

( )

𝑉

( )

( )

(1 − 𝜌 )

(6)

(7)

( ) ( )
, ,𝑍 ,

( )

( )

𝑉, 𝑉,
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(8)

𝑐𝑜𝑣 𝑍

( ) ( )
, ,𝑍 ,

=

𝑛 𝑛
{𝑛 𝑝̂ (𝑥̅ − 𝑋 ) + 𝑛 𝑝̂ (𝑥̅ − 𝑥̅ )}
𝑛 𝜎

Equation (7) gives the correlation between Z
between Z

( )
,

and Z

( )
, .

( )
,

and Z

( )
, .

(9)

Equation (8) is the correlation

In Equation (9), the covariance between Z

( )
,

and Z

( )
, ,

σ is the

MLE of σ for normally distributed endpoint under assumption that μ = μ , n is the number
of individuals from the selected treatment group , n is the number of individuals from
control group, p is the probability of success for binary endpoint in treatment group, p is
the probability of success for binary endpoint in control group, x is the treatment mean from
normally distributed endpoint, and x is the treatment mean value of short-term endpoint
among those classified as a success in the binary outcome. Additional specifics for
calculating these boundaries can be found in Stallard and Todd (2005).
(4) If the observed efficient Score at the current analysis crosses the upper boundary, the trial
stops and the treatment is determined to be superior to the control. If the test statistic crosses
below the lower boundary, the trial stops for futility.
(5) If the observed efficient Score at the current analysis crosses the upper boundary, the trial
stops and the treatment is determined to be superior to the control. If the test statistic crosses
below the lower boundary, the trial stops for futility.
(6) Steps (3), (4), and (5) continue until the maximum number of analyses is reached, which is
set before the trial begins.

R-package for A Confirmatory Seamless Phase II/Phase III Clinical Trial Design
Incorporating Short-Term Endpoint Information
To recreate the confirmatory seamless Phase II/Phase III clinical trial design described in
Stallard (2010), the design was rewritten in R to better test the method against new sets of data.
11

The design takes any number of treatments, provided that the treatments responses are normally
distributed. The steps for performing the design are described in steps 1-4.
(1) A double regression method is used to estimate the parameters of the model in the case where
secondary endpoint responses are available for all patients, and primary responses are
available for a subset of patients (Engel & Walstra, 1991). The parameter estimates for the
secondary endpoint are obtained from the regression of X on z where z is the vector that
indicates which treatment group allocation. The estimates for α, β, γ, and can be obtained
from regressing the primary outcome on z and X . In addition, the parameter 𝜎 , the variance
of the error term for 𝑌 , can be obtained. These estimates can then be used to obtain the
parameters used in the calculation of the test statistic by the Equations (10), (11), and (12).
𝐵 = 𝛽 + 𝛾𝑏

(10)

𝐴 = 𝛼 + 𝛾𝑎

(11)

𝑠 = 𝑠 + 𝛾𝑠

(12)

The variance of the parameter B is given by Equation (13).
𝑣𝑎𝑟 𝛽 + 𝛾 𝑣𝑎𝑟 𝑏 + 𝑏 𝑏𝑣𝑎𝑟(𝛾 ) + 2𝑏 𝑐𝑜𝑣 𝛽 , 𝛾

(13)

The distribution of the secondary endpoint X , and the conditional distribution of Y |X are
shown in Equation (14) and Equation (15).
𝑋 ~𝑁(𝑎 + 𝑏 𝑧 , 𝜎 )

12

(14)

(15)

(𝑌 |𝑋 = 𝑥 )~𝑁(𝛼 + 𝛽 𝑧 + 𝛾𝑥 , 𝜎 )
Once the parameter estimates are obtained, the test statistic at the first analysis, 𝑆 , is
calculated from Equation (16).
𝑆

=

𝐵

(16)

𝑣𝑎𝑟 𝐵

In Equation (16), 𝑘 is the corresponds to the treatment being used in the calculation of the
test statistic. After calculating the test statistics for each treatment, one treatment will be
selected to continue based on the largest value of the test statistic at the first analysis
(2) At this point in the analysis, stopping boundaries are calculated based on the information
from the selected treatment, while taking into account the total number of treatments used at
the start of the trial. Stopping boundaries are obtained so that they satisfy Equation (17) and
Equation (18).

𝑓[

]

=

⎡
⎤
𝐾
𝑥−𝑠
𝑥
𝑥
⎛
⎞
⎛
⎞
⎛
⎞
⎢
⎥
𝜙
𝛷
𝜑 𝜙
𝜑
𝜑 ⎢
𝜑 ⎥
2
⎝ 2 ⎠ ⎝ 2 ⎠ ⎣ ⎝ 2 ⎠⎦

𝑃𝑟(𝑆𝑡𝑜𝑝 𝑎𝑛𝑑 𝑟𝑒𝑗𝑒𝑐𝑡 𝑠𝑜𝑚𝑒 𝐻

𝑑𝑥

(17)

𝑖𝑛 𝑓𝑎𝑣𝑜𝑟 𝑜𝑓 𝐵 > 0 𝑏𝑦 𝑙𝑜𝑜𝑘 𝑗; 𝐻 ) = 𝛼 ∗ (𝑗)
(18)

𝑃𝑟(𝑆𝑡𝑜𝑝 𝑎𝑛𝑑 𝑟𝑒𝑗𝑒𝑐𝑡 𝑠𝑜𝑚𝑒 𝐻

𝑖𝑛 𝑓𝑎𝑣𝑜𝑟 𝑜𝑓 𝐵 < 0 𝑏𝑦 𝑙𝑜𝑜𝑘 𝑗; 𝐻 ) = 𝛼 ∗ (𝑗)

In Equation (17), 𝐾 is the number of treatments, φ is the variance of the selected treatment’s
test statistic at the first interim analysis given by
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. If the test statistic at the current

analysis crosses the upper boundary, the trial stops and the treatment is determined to be
effective. If the test statistic crosses below the lower boundary, the trial stops for futility.
(3) At the next analysis, recalculate the test statistics and stopping boundary values and compare
the test statistic against these stopping boundaries.
(4) Steps 1, 2, 3 and 4 continues until one of these situations occurs, or the trial reaches the
maximum number of interim analyses.
These general steps were re-created in an R-package. The package will be designed to take any
number of treatments, as well as different values for the known parameters in the design. Further
details for the methodology in this method can be found in Stallard (2010).

R-package for Statistical Analysis for Two-Stage Seamless Design with Different Study
Endpoints
Just as for Stallard and Todd (2005) and Stallard (2010), an R-package will be created to
replicate the design in Chow, Lu, and Tse (2007). To create this package, R code will be written
that follows the steps for the Two-Stage Seamless Design with Different Study Endpoints in
Chow, Lu, and Tse (2007). This package will take two treatments, and test for equality of the
two treatments. In addition, this design assumes that secondary endpoint information is available
for all patients, and that primary endpoint information is available for a subset of those patients.
The methodology for Chow, Lu and Tse (2007) is described in steps 1-3.
(1) The secondary and primary endpoints, denoted by x and y , follow the relationship defined
in Equation (19).
𝐸(𝑥 ) = 𝑣 𝑎𝑛𝑑 𝑉𝑎𝑟(𝑥 ) = 𝜏
(19)
𝐸(𝑦 ) = 𝜇 𝑎𝑛𝑑 𝑉𝑎𝑟(𝑦 ) = 𝜎
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Since long-term endpoint data are only available for a subset of the patients, the patients with
only short-term endpoint data have their long-term endpoint estimated by Equation (20).
𝑦 =𝛽 +𝛽 𝑥+𝜖

(20)

In Equation (20), β and β are assumed to come from a well-defined relationship and are
known beforehand.
(2) Once the estimated points are obtained, an estimate of the weighted mean and variance are
obtained for each treatment group with Equation (21) and Equation (23).
𝜇̂

= 𝜔 𝑦 + (1 − 𝜔 )𝑦

(21)

In Equation (21), 𝑦 is the weighted estimated mean, 𝑦 is the long-term endpoint mean, 𝑤 is
the weight given by Equation (22).
𝑛
𝑆

𝜔 = 𝑛
𝑚
+
𝑆
𝑆

𝑉 (𝜇̂

1
1
1
)= 𝑛
𝑚 1 + 4𝜔 (1 − 𝜔 ) 𝑛 − 1 + 𝑚 − 1
+
𝑆
𝑆

(22)

(23)

In Equation (22) and Equation (23), 𝑛 is the number of patients in the 𝑖𝑡ℎ treatment group at
the secondary endpoint and 𝑚 is the number of patients in the 𝑖𝑡ℎ treatment group at the
primary clinical endpoint. Additionally, 𝑆 and 𝑆 are the sample variances from the
estimated primary endpoint and the true primary endpoints, respectively.
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(3) Once the weighted mean and variance are calculated, an estimate for the test statistic can be
found using Equation (24).

𝑇 =

𝜇̂

− 𝜇̂

𝑉 (𝜇̂

) + 𝑉 (𝜇̂

(24)

)

The test statistic follows a standard normal distribution and the significance of the test can be
found using the interval in Equation (25) where V = V(μ

) + V(μ

) and z is the z

quantile a prespecified alpha level.
𝜇̂

− 𝜇̂

−𝑧

𝑉 , 𝜇̂

− 𝜇̂

+𝑧

𝑉

(25)

These steps will be coded in R in order to develop an R-package that gives practitioners the
ability to implement these statistical methods. More details behind this method can be found in
Chow, Lu, and Tse (2007).

Covariate Adaptive Randomization in a Seamless Phase II/Phase III Clinical Trial.
In order to determine if Type I error rates are conserved in a confirmatory seamless Phase
II/Phase III clinical trial that incorporates short-term endpoint information and uses covariate
adaptive randomization for allocation, study sample populations were simulated in R for 10,000
trials for each parameter setting, and for each covariate adaptive randomization scheme
described above. Using the Bernoulli covariate values defined above, the steps for this analysis
followed the same methodology as described in the confirmatory seamless Phase II/Phase III
clinical trial design in Stallard (2010), but the treatment responses followed the distribution in
Equation (3). The treatment groups were assigned using either the Pocock-Simons or the
stratified permuted block design. Each simulation tested for overall significance, and the Type I
16

error rate was taken as the proportion of trials that rejected the null hypothesis. The null
hypothesis in this case was that all treatments are equally effective.
For the stratified permuted block design, a block size of 20 was used with 4 stratification
levels.

RESULTS
Simulations were performed with 𝒃 = {(0,0,0)’, (0,0,0.333)’, (0,0, -0.333)’} and 𝑩 =
{(0,0,0)’} to test for Type I error. The overall Type I error rate was calculated as the number of
trials that the treatment effect exceeded the stopping boundary and therefore rejected the global
null hypothesis. Under simple randomization, the Type I Error Rate was 0.025 with a standard
error of 0.001. In the simulations performed under stratified permuted block randomization, the
Type I Error Rate was 0.016 with a standard error of 0.0002. In the simulations performed under
Pocock and Simon’s randomization, the Type I Error Rate was 0.027 with a standard error of
0.008.
Simulations were performed with 𝒃 = {(0,0,0)’, (0,0,0.333)’, (0,0, -0.333)’} and 𝑩 =
{(0,0,0.333)’} to test for power. Power was calculated as the proportion of simulations that
rejected the global null hypothesis and selected the third treatment as the selected treatment.
Under simple randomization, the power was 0.763 with a standard error of 0.009. Those
simulations performed under Pocock and Simon’s randomization resulted in a power of .598
with a standard error of 0.0064. stratified permuted block randomization resulted in a power of
0.621 with a standard error of 0.007
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Table 2: Type I Error Rates under Pocock & Simon's and Stratified Permuted Block
Randomization
𝜌

𝑏

0.5

0.000
0.333
-0.333
0.000
0.333
-0.333
0.000
0.333
-0.333
0.000
0.333
-0.333
0.000
0.333
-0.333

0.6

0.7

0.8

0.9

Pocock and Simon’s
Randomization
0.028
0.028
0.026
0.026
0.023
0.028
0.023
0.031
0.024
0.033
0.030
0.028
0.034
0.022
0.020

Type I Error Rates
Stratified Permuted
Block Randomization
0.016
0.015
0.016
0.015
0.014
0.016
0.016
0.017
0.014
0.015
0.014
0.016
0.017
0.017
0.018

Simple
Randomization
0.025
0.025
0.024
0.023
0.023
0.026
0.024
0.022
0.025
0.024
0.026
0.028
0.028
0.029
0.026

Table 3: Power Under Pocock and Simon's and Stratified Permuted Block Randomization
𝜌

𝑏

0.5

0.000
0.333
-0.333
0.000
0.333
-0.333
0.000
0.333
-0.333
0.000
0.333
-0.333
0.000
0.333
-0.333

0.6
0.7
0.8
0.9

Pocock and Simon’s
Randomization
0.564
0.569
0.574
0.584
0.577
0.580
0.594
0.590
0.589
0.615
0.617
0.619
0.627
0.629
0.640
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Power
Stratified Permuted
Block Randomization
0.587
0.585
0.594
0.601
0.594
0.599
0.620
0.622
0.628
0.629
0.642
0.642
0.666
0.656
0.656

Simple
Randomization
0.720
0.718
0.722
0.735
0.741
0.733
0.754
0.747
0.763
0.788
0.785
0.785
0.821
0.814
0.820

DISCUSSION
Using Pocock and Simon’s randomization to balance treatment assignments between
three treatment groups with two covariates, Type I error was not equal to Type I error under
simple randomization. This adaptive method approximately inflated the Type I error in this
simulation. This conclusion is consistent with previous research on Pocock and Simon’s
randomization procedure, where Type I error rates were over-estimated in clinical trial
simulations. If Pocock and Simon’s randomization is used to balance treatment groups, there is a
higher chance of exceeding the stopping boundaries in the Phase III portion of the trial. This is
concerning as trials under this randomization scheme might have more false positives, and
ultimately might falsely conclude that a treatment is determined to be effective. The Type I error
rate did not drastically change with variations in correlation between the long-term and shortterm endpoints. The power under Pocock and Simon’s randomization procedure did not reach the
same level as with simple randomization. However, the power did increase with the correlation
between the primary and secondary clinical endpoints.
Using stratified permuted block randomization with a block size of 20 to balance
treatment assignments between three treatment groups, Type I error rates were not held at the
same level as with simple randomization. Type I error rates under stratified permuted block
randomization underestimated the Type I error rate compared to simple randomization. One
possible explanation for this result is that this randomization procedure results in different
numbers of treatment assignments. As a result, the block size isn’t always a multiple of the
number of treatment groups; therefore, there are some blocks that won’t be filled. Another
possible explanation is that the different number of patients per treatment group results in largely
different test statistics for this clinical trial design. This trial design uses an estimate for Fisher’s
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information that is a function of the progress in the trial. Therefore, if there are different numbers
of patients per treatment group, then the Fisher’s information will be different for each treatment
group. This contrasts with the original design under (Stallard, 2009) that uses equal treatment
assignments between treatment groups. Similar to the results from Pocock and Simon’s
randomization, the power under stratified permuted block randomization did not reach the same
level as with simple randomization. However, the power under this method was slightly higher
compared to Pocock and Simon’s method.

CONCLUSION
As shown in above, Type I error rates do not appear to be conserved when randomization
is performed according to Pocock and Simon’s randomization or stratified permuted block
randomization. Further analysis needs to be performed that incorporates these two methods to
understand how to control Type I error rates with covariate adaptive randomization.
Future analysis of Pocock and Simon’s method could be to analyze the randomization
scheme under different covariate weights, or to include Bootstrap sampling to estimate the
variance of the test statistic. If this method controls control Type I error rates at the prespecified
level, then this method would be useful to minimize the imbalance between treatment groups in a
trial that considers more than two treatment groups, over multiple phases.
Using Bootstrap sampling to estimate the variance of the long-term endpoint test statistic
could be a way to better estimate the Type I error at the prespecified level of 0.025. Although
there is a closed-form solution for the variance of the long-term endpoint test statistic 𝑍 , the
formula assumes that treatment group sizes equal across all treatments. Therefore, using a
bootstrap estimate of variance might result in better construction of stopping boundaries and test
statistics.
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There are many other opportunities for future studies. Three treatment groups and a
control group were tested in this analysis; however, different numbers of treatment groups could
be tested in future analysis to determine the effect on Type I error. In addition, this method
assumes that only one treatment continues past the first interim analysis. In future studies, more
than one treatment group could continue to the next phase of the trial. Future analysis could test
the results of this method under a wider range of correlations, parameter settings, and covariates.
In Pocock and Simon’s randomization, there are multiple ways to calculate the amount of
variation and the total amount of imbalance between treatment groups. Although a range, and
non-weighted sum were chosen in this analysis, other methods could be used to determine the
amount of imbalance and determine the next treatment group. In stratified permuted block
randomization, a random block size could be used to determine the effect on Type I error.
R-packages that follow the designs in Stallard and Todd (2005), Stallard (2010), and
Chow, Lu, and Tse (2007) are available from the author.

ETHICAL AND SAFETY CONSIDERATIONS
There are no ethnical concerns and no concerns about keeping records confidential. No
data will be collected from human subjects since this is a simulated study.
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